AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Cingulate Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG012G40NT6
4.98▲ 0.32 (6.87%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
4.66
Day's Range
4.61 – 4.98
52-Week Range
3.16 – 10.92
Volume
79.1K
Avg Volume
94.3K
Share Statistics
Shares Outstanding
Employees
14
Exchange
XNAS
Listed
2021-12-08
Share count as of August 12, 2026

Cingulate Inc. Common Stock (CING) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Cingulate Inc. Common Stock (CING)
What is Cingulate Inc. Common Stock's Market Cap?
Cingulate Inc. Common Stock's Market Cap is $72.4M, based on as-reported figures from SEC (XBRL) filings.
What is Cingulate Inc. Common Stock's Enterprise Value?
Cingulate Inc. Common Stock's Enterprise Value is $44.0M, based on as-reported figures from SEC (XBRL) filings.
What is Cingulate Inc. Common Stock's EV / EBITDA?
Cingulate Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Cingulate Inc. Common Stock's Net Income (TTM)?
Cingulate Inc. Common Stock's Net Income (TTM) is -$28.8M, based on as-reported figures from SEC (XBRL) filings.
What is Cingulate Inc. Common Stock's EBITDA?
Cingulate Inc. Common Stock's EBITDA is -$24.5M, based on as-reported figures from SEC (XBRL) filings.
What is Cingulate Inc. Common Stock's Diluted EPS (TTM)?
Cingulate Inc. Common Stock's Diluted EPS (TTM) is -1.98, based on as-reported figures from SEC (XBRL) filings.
What is Cingulate Inc. Common Stock's Net Debt?
Cingulate Inc. Common Stock's Net Debt is -$28.4M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CINGAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and Development Expense
Selling, General and Administrative Expense
Operating loss
Change in fair value of derivative——
Interest Expense——
Loss before income taxes
Net loss and comprehensive loss
Earnings Per Share (Basic)
Earnings Per Share (Diluted)